GUD Share Price Performance
CA$8.18
2.42 (42.01%)
25.6% undervalued intrinsic discount
CA$11.00
Fair Value
Price CA$8.18
AnalystHighTarget CA$11.00
AnalystConsensusTarget CA$7.74
AnalystLowTarget CA$6.15
Fair ValueCA$11.00
Share Pricen/a
Knight Therapeutics Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
GUD Community Narratives
AN
Fair Value
·Fair Value CA$11 25.6% undervalued intrinsic discount
Aging Global Populations And Latin America Will Expand Pharma Access
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value CA$7.8 4.9% overvalued intrinsic discount
Rising Latin America Demand Will Expand Specialty Pharma Reach
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value
·Fair Value CA$6.15 33.0% overvalued intrinsic discount
Global Pricing Scrutiny And Latin American Risks Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Global Populations And Latin America Will Expand Pharma Access
Key Takeaways Early entry into high-value specialty drug markets and effective integration of acquisitions position Knight for sustained outperformance and operational leverage in Latin America and Canada. Strong regulatory expertise, expanded portfolio, and strategic manufacturing access enable Knight to capitalize on innovative therapies and drive multi-year compounding earnings growth.Read more
AN
CA$11
25.6% undervalued intrinsic discount
Fair Value
Profit Margin
7.43%
Future PE
28.13x
Price in 2029
CA$13.14
Global Pricing Scrutiny And Latin American Risks Will Erode Margins
Key Takeaways Margin pressures are mounting due to unfavorable product mix, competition, and regulatory risk, threatening profitability and constraining future revenue growth. Heavy reliance on external products and unstable emerging markets increases vulnerability to revenue volatility, supply disruptions, and adverse economic or political shifts.Read more
AN
CA$6.15
33.0% overvalued intrinsic discount
Fair Value
Revenue
7.88% p.a.
Profit Margin
5.25%
Future PE
27.74x
Price in 2028
CA$7.3
Rising Latin America Demand Will Expand Specialty Pharma Reach
Key Takeaways Expanding specialty pharma portfolio and successful product launches drive growth, margin improvements, and geographic diversification, especially in emerging Latin American markets. Strong financial position and M&A strategy provide capital flexibility, supporting ongoing innovation, higher pricing power, and resilient profit margins.Read more
AN
CA$7.8
4.9% overvalued intrinsic discount
Fair Value
Revenue
9.21% p.a.
Profit Margin
5.12%
Future PE
34.72x
Price in 2028
CA$9.25
Trending Discussion
Recently Updated Narratives
AN
GUD: Higher 2026 Margins And Buybacks Will Support Bullish Repricing
Fair Value: CA$11 25.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Global Pricing Scrutiny And Latin American Risks Will Erode Margins
Fair Value: CA$6.15 33.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Latin America Demand Will Expand Specialty Pharma Reach
Fair Value: CA$7.8 4.9% overvalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Knight Therapeutics Inc. Key Details
About GUD
- Founded
- 2013
- Employees
- 830
- CEO
- WebsiteView website
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
